TRVN:OTCMKTS
Trevena Inc
US$Â 0.066
0.00%
(0.00) Siku 1
12 Okt, 14:57:26 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya TRVN...
Mtaji wa soko
elfu 57.01
Wastani wa kiasi cha mauzo
210.00
Kiasi cha mauzo ya hisa
9.00
Juu kwa wiki 52
US$Â 1.50
Chini kwa wiki 52
US$Â 0.00
Beta
1.07
Hisa za wawekezaji
elfu 864.00
Idadi ya wafanyakazi
23
Mtaji wa soko
elfu 57.01
Wastani wa kiasi cha mauzo
210.00
Kiasi cha mauzo ya hisa
9.00
Juu kwa wiki 52
US$Â 1.50
Chini kwa wiki 52
US$Â 0.00
Beta
1.07
Hisa za wawekezaji
elfu 864.00
Idadi ya wafanyakazi
23
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Yahoo Finance
·
dakika 8 zilizopita
Stock market today: Dow, S&P 500, Nasdaq futures mixed amid volatile week
The Globe and Mail
·
dakika 48 zilizopita
TNL Mediagene Regains Compliance with Nasdaq Minimum Bid Price Requirement
Seeking Alpha
·
dakika 53 zilizopita
Dow Jones Bullish Catch-Up Over Nasdaq 100 As AI Rotation Accelerates
Investor's Business Daily
·
saa 8 zilizopita
Futures Mixed; Anthropic Value, Tesla Roadster In Focus
Wasifu
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Kuhusu Trevena Inc
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazi23
Lilianzishwa2007
Makao makuuAtlanta, Georgia, Marekani
Sekta-
Tovutitrevena.com